Hypertension and dyslipidemia often coexist in hypertensive patients. Hypertensive patients hospitalized in our department with dyslipidemia accounted for 42.32%. At the same blood pressure level, the more serious the dyslipidemia, the higher the risk of cardiovascular disease. Therefore, hypertensive patients should pay more attention to their lipid status. In 1998, 19,342 hypertensive patients were enrolled in the United Kingdom, of whom 10,305 were treated with the lipid-regulating drug atorvastatin, to study whether lipid-regulating therapy could provide more cardiovascular benefits. 2 years ahead of schedule, the results were published in October 2002: hypertensive patients with normal or mildly abnormal lipids who were treated with the lipid-regulating drug atorvastatin reduced the risk of fatal coronary heart disease and non-fatal myocardial infarction, as compared to those who were treated with a placebo. nonfatal myocardial infarction by 36%, fatal and nonfatal stroke by 27%, and cardiovascular events and revascularization by 21%. It is worth noting that these results were obtained on the basis of aggressive, tight control of hypertension, and the results clearly show that the addition of atorvastatin therapy to antihypertensive therapy prevents more myocardial infarctions and strokes, even with normal or mildly abnormal lipids. Therefore, the majority of hypertensive patients should recognize the risk of combined dyslipidemia, and actively screen their blood lipids, and if dyslipidemia is found, they should receive lipid-regulating therapy while actively lowering blood pressure. In recent years, the incidence of ischemic stroke caused by dyslipidemia and atherosclerosis has been on the rise in China, and in the past, people did not recognize the importance of lipid regulating therapy for stroke prevention, so this is of more profound significance to us.